Meeting Coverage:

American Academy of Ophthalmology

AAO: 2019

Key Results From the Bimatoprost SR Phase 3 Study

Show Description +

Randy Craven, MD, reviews phase 3 data from a pair of clinical trials that evaluated the safety and efficacy of the bimatoprost sustained-release implant (Allergan). Dr. Craven discusses the primary endpoint that was met and the safety profile of the implant.

Posted: 10/02/2019

Keywords:

Medical Studies

Up Next


Advanced Diagnostics in Refractive Surgery: Epithelial Mapping and Phakic IOL Sizing

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

Efficacy of Presbyond for the Correction of Presbyopia

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

Autonomous AI in Ophthalmology

Michael D. Abramoff, MD, PhD

CXL for Infectious Keratitis

Farhad Hafezi, MD, PhD, FARVO

MIGS and Medications

Alex Huang, MD

Controlling Wound Healing Following PRK

Farhad Hafezi, MD, PhD, FARVO

A New Anti-VEGF Option

J. Fernando Arevalo, MD, PhD, FACS

PANORAMA Study Data

Rishi P. Singh, MD

Gene Therapy for Wet AMD

Szilard Kiss, MD

ABC to Block VEGF-A Isoforms

Charles C. Wykoff, MD, PhD

Surgery for Viral Retinitis

J. Fernando Arevalo, MD, PhD, FACS

Iridocorneal Endothelial Syndrome

Lauren S. Blieden, MD

Key Results From the Bimatoprost SR Phase 3 Study

Randy Craven, MD, reviews phase 3 data from a pair of clinical trials that evaluated the safety and efficacy of the bimatoprost sustained-release implant (Allergan). Dr. Craven discusses the primary endpoint that was met and the safety profile of the implant.

Posted: 10/02/2019

Keywords:

Medical Studies

Please log in to leave a comment.

More From AAO: 2019 Coverage

A New Anti-VEGF Option

J. Fernando Arevalo, MD, PhD, FACS